X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (XFOR)

CUSIP: 98420X103

Q2 2022 13F Holders as of 30 Jun 2022

Holder snapshot 7 signals
Share change
-301,087
Put/Call ratio
129%
SEC-reported price per share
$0.96
Number of holders
44
Value change
-$680,561
Number of buys
13
Open additional details 1 more signal available
Number of sells
21
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
94,372,096

Security key

98420X103

Report period

Q2 2022

Institutions

44

Top holders

10

Ownership snapshot

Top reported holders of XFOR - X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Bain Capital Life Science...
Disclosed value leader
Bain Capital Life Science...
Comparable rows
0/15
Latest evidence
31 Mar 2022
13F Highest disclosed value: $5,284,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Bain Capital Life Sciences Investors, LLC has the largest disclosed position value at $5.28M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Bain Capital Life Sciences Investors, LLC's linked filing trail.
Disclosed position value Top 5
Bain Capital Life Sciences Invest... $5.28M
Tri Locum Partners LP $3.01M
Point72 Asset Management, L.P. $2.86M
ORBIMED ADVISORS LLC $2.4M
Ikarian Capital, LLC $2.4M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Bain Capital Life Sciences Investors, LLC
13F
Company
13F
—
denominator unverified
$5,284,000
3,019,540 shares
— 31 Mar 2022
Tri Locum Partners LP
13F
Company
13F
—
denominator unverified
$3,006,000
1,717,589 shares
— 31 Mar 2022
Point72 Asset Management, L.P.
13F
Company
13F
—
denominator unverified
$2,858,000
1,633,204 shares
— 31 Mar 2022
ORBIMED ADVISORS LLC
13F
Company
13F
—
denominator unverified
$2,404,000
1,373,849 shares
— 31 Mar 2022
Ikarian Capital, LLC
13F
Company
13F
—
denominator unverified
$2,402,000
1,372,022 shares
— 31 Mar 2022
AXA S.A.
13F
Company
13F
—
denominator unverified
$2,014,845
1,151,340 shares
— 31 Mar 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
44
Shares
16,046,519
Rows available
44
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2022 vs Q1 2026 Across Filers

Q1 2026 holders
2
Q2 2022 holders
44
Holder diff
42
Investor Q1 2026 Shares Q2 2022 Shares Share Diff Share Chg % Q1 2026 value Q2 2022 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .